Combination Immunotherapy and Chemotherapy for Cancer

Antibodies were delivered intraperitoneally in 100 μl of phosphate-buffered saline (PBS). αCD4 (catalog no. GK1.5, BioXCell) and αCD8 (catalog no. 2.43, BioXCell) were administered at 200 μg every 4 d. αPD-1 (catalog no. 29F.1A12, BioXCell) was administered at 200 μg 3× a week. αCTLA (catalog no. 9H10, BioXCell) was administered at an initial dose of 200 μg, with subsequent doses at 100 μg, 3× a week. Oxaliplatin (Sigma-Aldrich) and cyclophosphamide (Sigma-Aldrich) (Oxa/Cyc) were co-delivered intraperitoneally in 100 μl of PBS at 2.5 mg per kg body weight and 50 mg per kg body weight, respectively, once a week for 3 weeks, as previously described^{42 (link)}.